Clinical Laserthermia Systems and Toronto General Hospital Begin Clinical Study for MRI-Guided Laser Ablation Treatment of Prostate Cancer
Framingham, MA – April 17, 2018- Clinical Laserthermia Systems Americas, Inc . (CLS) a subsidiary of CLS AB in Lund, Sweden, today announced the commencement of a clinical study with Toronto General Hospital in Canada investigating MRI-guided, focal laser ablation (FLA) treatments for prostate cancer. The study has been approved by Health Canada and its results will be published on the National Institute of Health Web site:www.clinicaltrials.gov. Starting in April 2018, twenty-five patients will participate in a 24-month study at the hospital to evaluate the